{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:59:11Z","timestamp":1761897551289,"version":"3.37.3"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:00:00Z","timestamp":1620950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:00:00Z","timestamp":1620950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s10067-021-05686-8","type":"journal-article","created":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T18:02:25Z","timestamp":1621015345000},"page":"3989-4005","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of jakinibs in rheumatoid arthritis: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8840-3397","authenticated-orcid":false,"given":"Yufeng","family":"Yin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengru","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erye","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michun","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,14]]},"reference":[{"issue":"13","key":"5686_CR1","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"D Aletaha","year":"2018","unstructured":"Aletaha D, Smolen JS (2018) Diagnosis and management of rheumatoid arthritis: a review. JAMA. 320(13):1360\u20131372","journal-title":"JAMA."},{"issue":"2","key":"5686_CR2","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.immuni.2017.02.006","volume":"46","author":"GS Firestein","year":"2017","unstructured":"Firestein GS, McInnes IB (2017) Immunopathogenesis of rheumatoid arthritis. Immunity. 46(2):183\u2013196","journal-title":"Immunity."},{"issue":"6","key":"5686_CR3","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poor G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76(6):960\u2013977","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"5686_CR4","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nrrheum.2017.95","volume":"13","author":"GR Burmester","year":"2017","unstructured":"Burmester GR, Bijlsma JWJ, Cutolo M, McInnes IB (2017) Managing rheumatic and musculoskeletal diseases - past, present and future. Nat Rev Rheumatol. 13(7):443\u2013448","journal-title":"Nat Rev Rheumatol."},{"key":"5686_CR5","unstructured":"Garces S, Demengeot J (2018) The immunogenicity of biologic therapies. Curr Probl Dermatol.:5337\u20135348"},{"key":"5686_CR6","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/ar2666","volume":"11 Suppl 1","author":"A Rubbert-Roth","year":"2009","unstructured":"Rubbert-Roth A, Finckh A (2009) Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther 11 Suppl 1:S1","journal-title":"Arthritis Res Ther"},{"key":"5686_CR7","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.3389\/fphar.2018.01070","volume":"9","author":"M Manova","year":"2018","unstructured":"Manova M, Savova A, Vasileva M, Terezova S, Kamusheva M, Grekova D, Petkova V, Petrova G (2018) Comparative price analysis of biological products for treatment of rheumatoid arthritis. Front Pharmacol. 9:1070","journal-title":"Front Pharmacol."},{"key":"5686_CR8","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.3389\/fimmu.2019.02847","volume":"10","author":"F Solimani","year":"2019","unstructured":"Solimani F, Meier K, Ghoreschi K (2019) Emerging topical and systemic JAK inhibitors in dermatology. Front Immunol. 10:2847","journal-title":"Front Immunol."},{"issue":"12","key":"5686_CR9","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd.2017.201","volume":"16","author":"DM Schwartz","year":"2017","unstructured":"Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O'Shea JJ (2017) JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 16(12):843\u2013862","journal-title":"Nat Rev Drug Discov."},{"issue":"6","key":"5686_CR10","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nbt0611-467","volume":"29","author":"K Garber","year":"2011","unstructured":"Garber K (2011) Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis. Nat Biotechnol. 29(6):467\u2013468","journal-title":"Nat Biotechnol."},{"issue":"11","key":"5686_CR11","doi-asserted-by":"publisher","first-page":"102390","DOI":"10.1016\/j.autrev.2019.102390","volume":"18","author":"Y Jamilloux","year":"2019","unstructured":"Jamilloux Y, El Jammal T, Vuitton L, Gerfaud-Valentin M, Kerever S, Seve P (2019) JAK inhibitors for the treatment of autoimmune and inflammatory diseases. Autoimmunity reviews. 18(11):102390","journal-title":"Autoimmunity reviews."},{"issue":"2","key":"5686_CR12","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1136\/ard.2009.108159","volume":"69","author":"JH Coombs","year":"2010","unstructured":"Coombs JH, Bloom BJ, Breedveld FC, Fletcher MP, Gruben D, Kremer JM, Burgos-Vargas R, Wilkinson B, Zerbini CA, Zwillich SH (2010) Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 69(2):413\u2013416","journal-title":"Ann Rheum Dis."},{"issue":"5","key":"5686_CR13","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s40259-016-0190-5","volume":"30","author":"S Nakayamada","year":"2016","unstructured":"Nakayamada S, Kubo S, Iwata S, Tanaka Y (2016) Recent progress in JAK inhibitors for the treatment of rheumatoid arthritis. Biodrugs. 30(5):407\u2013419","journal-title":"Biodrugs."},{"issue":"10","key":"5686_CR14","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","volume":"58","author":"K Bechman","year":"2019","unstructured":"Bechman K, Subesinghe S, Norton S, Atzeni F, Galli M, Cope AP, Winthrop KL, Galloway JB (2019) A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford). 58(10):1755\u20131766","journal-title":"Rheumatology (Oxford)."},{"issue":"3","key":"5686_CR15","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/jcpt.12795","volume":"44","author":"M Camean-Castillo","year":"2019","unstructured":"Camean-Castillo M, Gimeno-Ballester V, Rios-Sanchez E, Fenix-Caballero S, Vazquez-Real M, Alegre-Del RE (2019) Network meta-analysis of tofacitinib versus biologic treatments in moderate-to-severe rheumatoid arthritis patients. J Clin Pharm Ther. 44(3):384\u2013396","journal-title":"J Clin Pharm Ther."},{"issue":"8","key":"5686_CR16","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1136\/annrheumdis-2018-214846","volume":"78","author":"W Xie","year":"2019","unstructured":"Xie W, Huang Y, Xiao S, Sun X, Fan Y, Zhang Z (2019) Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis. 78(8):1048\u20131054","journal-title":"Ann Rheum Dis."},{"issue":"16","key":"5686_CR17","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1001\/jama.2015.3656","volume":"313","author":"LA Stewart","year":"2015","unstructured":"Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF (2015) Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 313(16):1657\u20131665","journal-title":"JAMA."},{"issue":"1","key":"5686_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 17(1):1\u201312","journal-title":"Control Clin Trials."},{"issue":"1","key":"5686_CR19","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","volume":"76","author":"M Dougados","year":"2017","unstructured":"Dougados M, van der Heijde D, Chen YC, Greenwald M, Drescher E, Liu J, Beattie S, Witt S, de la Torre I, Gaich C, Rooney T, Schlichting D, de Bono S, Emery P (2017) Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis. 76(1):88\u201395","journal-title":"Ann Rheum Dis."},{"issue":"3","key":"5686_CR20","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/art.39953","volume":"69","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M, Zerbini CA, Gurbuz S, Dickson C, de Bono S, Schlichting D, Beattie S, Kuo WL, Rooney T, Macias W, Takeuchi T (2017) Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis & Rheumatology (Hoboken, NJ) 69(3):506\u2013517","journal-title":"Arthritis & Rheumatology (Hoboken, NJ)"},{"issue":"13","key":"5686_CR21","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","volume":"374","author":"MC Genovese","year":"2016","unstructured":"Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, Beattie SD, Koch AE, Cardillo TE, Rooney TP, Macias WL, de Bono S, Schlichting DE, Smolen JS (2016) Baricitinib in Patients with refractory rheumatoid arthritis. N Engl J Med. 374(13):1243\u20131252","journal-title":"N Engl J Med."},{"issue":"2","key":"5686_CR22","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1136\/annrheumdis-2014-206478","volume":"74","author":"EC Keystone","year":"2015","unstructured":"Keystone EC, Taylor PC, Drescher E, Schlichting DE, Beattie SD, Berclaz PY, Lee CH, Fidelus-Gort RK, Luchi ME, Rooney TP, Macias WL, Genovese MC (2015) Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis. 74(2):333\u2013340","journal-title":"Ann Rheum Dis."},{"issue":"7","key":"5686_CR23","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, Reyes Gonzaga J, Yakushin S, Ishii T, Emoto K, Beattie S, Arora V, Gaich C, Rooney T, Schlichting D, Macias WL, de Bono S, Tanaka Y (2017) Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 376(7):652\u2013662","journal-title":"N Engl J Med."},{"issue":"2","key":"5686_CR24","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/art.38949","volume":"67","author":"RM Fleischmann","year":"2015","unstructured":"Fleischmann RM, Damjanov NS, Kivitz AJ, Legedza A, Hoock T, Kinnman N (2015) A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis. Arthritis & rheumatology (Hoboken, NJ) 67(2):334\u2013343","journal-title":"Arthritis & rheumatology (Hoboken, NJ)"},{"issue":"1","key":"5686_CR25","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/art.39473","volume":"68","author":"MC Genovese","year":"2016","unstructured":"Genovese MC, van Vollenhoven RF, Pacheco-Tena C, Zhang Y, Kinnman N (2016) VX-509 (Decernotinib), an oral selective JAK-3 Inhibitor, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis & rheumatology (Hoboken, NJ) 68(1):46\u201355","journal-title":"Arthritis & rheumatology (Hoboken, NJ)"},{"issue":"4","key":"5686_CR26","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1001\/jama.2019.9055","volume":"322","author":"MC Genovese","year":"2019","unstructured":"Genovese MC, Kalunian K, Gottenberg JE, Mozaffarian N, Bartok B, Matzkies F, Gao J, Guo Y, Tasset C, Sundy JS, de Vlam K, Walker D, Takeuchi T (2019) Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial. JAMA. 322(4):315\u2013325","journal-title":"JAMA."},{"issue":"6","key":"5686_CR27","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1136\/annrheumdis-2016-210105","volume":"76","author":"A Kavanaugh","year":"2017","unstructured":"Kavanaugh A, Kremer J, Ponce L, Cseuz R, Reshetko OV, Stanislavchuk M, Greenwald M, Van der Aa A, Vanhoutte F, Tasset C, Harrison P (2017) Filgotinib (GLPG0634\/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Ann Rheum Dis. 76(6):1009\u20131019","journal-title":"Ann Rheum Dis."},{"issue":"6","key":"5686_CR28","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1136\/annrheumdis-2016-210104","volume":"76","author":"R Westhovens","year":"2017","unstructured":"Westhovens R, Taylor PC, Alten R, Pavlova D, Enriquez-Sosa F, Mazur M, Greenwald M, Van der Aa A, Vanhoutte F, Tasset C, Harrison P (2017) Filgotinib (GLPG0634\/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1). Ann Rheum Dis. 76(6):998\u20131008","journal-title":"Ann Rheum Dis."},{"issue":"4","key":"5686_CR29","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/art.39955","volume":"69","author":"AJ Kivitz","year":"2017","unstructured":"Kivitz AJ, Gutierrez-Urena SR, Poiley J, Genovese MC, Kristy R, Shay K, Wang X, Garg JP, Zubrzycka-Sienkiewicz A (2017) peficitinib, a JAK inhibitor, in the treatment of moderate-to-severe rheumatoid arthritis in patients with an inadequate response to methotrexate. Arthritis & rheumatology (Hoboken, NJ) 69(4):709\u2013719","journal-title":"Arthritis & rheumatology (Hoboken, NJ)"},{"issue":"10","key":"5686_CR30","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1136\/annrheumdis-2019-215164","volume":"78","author":"T Takeuchi","year":"2019","unstructured":"Takeuchi T, Tanaka Y, Tanaka S, Kawakami A, Iwasaki M, Katayama K, Rokuda M, Izutsu H, Ushijima S, Kaneko Y, Shiomi T, Yamada E, van der Heijde D (2019) Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan. Ann Rheum Dis. 78(10):1305\u20131319","journal-title":"Ann Rheum Dis."},{"issue":"6","key":"5686_CR31","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1136\/annrheumdis-2015-208279","volume":"75","author":"T Takeuchi","year":"2016","unstructured":"Takeuchi T, Tanaka Y, Iwasaki M, Ishikura H, Saeki S, Kaneko Y (2016) Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study. Ann Rheum Dis. 75(6):1057\u20131064","journal-title":"Ann Rheum Dis."},{"issue":"9865","key":"5686_CR32","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","volume":"381","author":"GR Burmester","year":"2013","unstructured":"Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, Gruben D, Wallenstein G, Krishnaswami S, Zwillich SH, Koncz T, Soma K, Bradley J, Mebus C (2013) Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 381(9865):451\u2013460","journal-title":"Lancet."},{"issue":"6","key":"5686_CR33","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa1109071","volume":"367","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, Gruben D, Wallenstein GV, Zwillich SH, Kanik KS (2012) Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 367(6):495\u2013507","journal-title":"N Engl J Med."},{"issue":"3","key":"5686_CR34","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/art.33383","volume":"64","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann R, Cutolo M, Genovese MC, Lee EB, Kanik KS, Sadis S, Connell CA, Gruben D, Krishnaswami S, Wallenstein G, Wilkinson BE, Zwillich SH (2012) Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum. 64(3):617\u2013629","journal-title":"Arthritis Rheum."},{"issue":"4","key":"5686_CR35","doi-asserted-by":"publisher","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","volume":"159","author":"J Kremer","year":"2013","unstructured":"Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E, Isaacs JD, Gruben D, Wallenstein G, Krishnaswami S, Zwillich SH, Koncz T, Riese R, Bradley J (2013) Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 159(4):253\u2013261","journal-title":"Ann Intern Med."},{"issue":"4","key":"5686_CR36","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/art.33419","volume":"64","author":"JM Kremer","year":"2012","unstructured":"Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez-Reino J, Gruben D, Kanik KS, Krishnaswami S, Pascual-Ramos V, Wallenstein G, Zwillich SH (2012) A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum. 64(4):970\u2013981","journal-title":"Arthritis Rheum."},{"issue":"25","key":"5686_CR37","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","volume":"370","author":"EB Lee","year":"2014","unstructured":"Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, Koncz T, Krishnaswami S, Wallenstein GV, Zang C, Zwillich SH, van Vollenhoven RF (2014) Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 370(25):2377\u20132386","journal-title":"N Engl J Med."},{"issue":"8","key":"5686_CR38","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1002\/acr.20494","volume":"63","author":"Y Tanaka","year":"2011","unstructured":"Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich SH (2011) Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken). 63(8):1150\u20131158","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"4","key":"5686_CR39","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3109\/14397595.2014.995875","volume":"25","author":"Y Tanaka","year":"2015","unstructured":"Tanaka Y, Takeuchi T, Yamanaka H, Nakamura H, Toyoizumi S, Zwillich S (2015) Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study. Mod Rheumatol. 25(4):514\u2013521","journal-title":"Mod Rheumatol."},{"issue":"3","key":"5686_CR40","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/art.37816","volume":"65","author":"D van der Heijde","year":"2013","unstructured":"van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, Cardiel MH, Cohen S, Nash P, Song YW, Tegzova D, Wyman BT, Gruben D, Benda B, Wallenstein G, Krishnaswami S, Zwillich SH, Bradley JD, Connell CA (2013) Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 65(3):559\u2013570","journal-title":"Arthritis Rheum."},{"issue":"6","key":"5686_CR41","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJMoa1112072","volume":"367","author":"RF van Vollenhoven","year":"2012","unstructured":"van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garcia Meijide JA, Wagner S, Forejtova S, Zwillich SH, Gruben D, Koncz T, Wallenstein GV, Krishnaswami S, Bradley JD, Wilkinson B (2012) Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 367(6):508\u2013519","journal-title":"N Engl J Med."},{"issue":"10139","key":"5686_CR42","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","volume":"391","author":"GR Burmester","year":"2018","unstructured":"Burmester GR, Kremer JM, Van den Bosch F, Kivitz A, Bessette L, Li Y, Zhou Y, Othman AA, Pangan AL, Camp HS (2018) Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 391(10139):2503\u20132512","journal-title":"Lancet."},{"issue":"12","key":"5686_CR43","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1002\/art.39808","volume":"68","author":"MC Genovese","year":"2016","unstructured":"Genovese MC, Smolen JS, Weinblatt ME, Burmester GR, Meerwein S, Camp HS, Wang L, Othman AA, Khan N, Pangan AL, Jungerwirth S (2016) Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a phase IIb study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis & rheumatology (Hoboken, NJ) 68(12):2857\u20132866","journal-title":"Arthritis & rheumatology (Hoboken, NJ)"},{"issue":"10139","key":"5686_CR44","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","volume":"391","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, Fleischmann R, Combe B, Hall S, Rubbert-Roth A, Zhang Y, Zhou Y, Mohamed MF, Meerwein S, Pangan AL (2018) Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 391(10139):2513\u20132524","journal-title":"Lancet."},{"issue":"12","key":"5686_CR45","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1002\/art.39801","volume":"68","author":"JM Kremer","year":"2016","unstructured":"Kremer JM, Emery P, Camp HS, Friedman A, Wang L, Othman AA, Khan N, Pangan AL, Jungerwirth S, Keystone EC (2016) A phase IIb study of ABT-494, a selective JAK-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy. Arthritis & rheumatology (Hoboken, NJ) 68(12):2867\u20132877","journal-title":"Arthritis & rheumatology (Hoboken, NJ)"},{"issue":"10188","key":"5686_CR46","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","volume":"393","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, Pangan AL, Emery P, Rigby W, Tanaka Y, Vargas JI, Zhang Y, Damjanov N, Friedman A, Othman AA, Camp HS, Cohen S (2019) Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 393(10188):2303\u20132311","journal-title":"Lancet."},{"issue":"Suppl 1","key":"5686_CR47","doi-asserted-by":"publisher","first-page":"i4","DOI":"10.1093\/rheumatology\/key432","volume":"58","author":"M Gadina","year":"2019","unstructured":"Gadina M, Le MT, Schwartz DM, Silvennoinen O, Nakayamada S, Yamaoka K, O'Shea JJ (2019) Janus kinases to jakinibs: from basic insights to clinical practice. Rheumatology (Oxford). 58(Suppl 1):i4\u2013i16","journal-title":"Rheumatology (Oxford)."},{"issue":"12","key":"5686_CR48","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s10067-009-1233-9","volume":"28","author":"A Wiens","year":"2009","unstructured":"Wiens A, Correr CJ, Venson R, Grochocki MC, Otuki MF, Pontarolo R (2009) A meta-analysis of the efficacy and safety of using infliximab for the treatment of rheumatoid arthritis. Clin Rheumatol. 28(12):1365\u20131373","journal-title":"Clin Rheumatol."},{"issue":"10086","key":"5686_CR49","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/S0140-6736(17)31491-5","volume":"389","author":"GR Burmester","year":"2017","unstructured":"Burmester GR, Pope JE (2017) Novel treatment strategies in rheumatoid arthritis. Lancet. 389(10086):2338\u20132348","journal-title":"Lancet."},{"key":"5686_CR50","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1476-9255-7-41","volume":"7","author":"DM Meyer","year":"2010","unstructured":"Meyer DM, Jesson MI, Li X, Elrick MM, Funckes-Shippy CL, Warner JD, Gross CJ, Dowty ME, Ramaiah SK, Hirsch JL, Saabye MJ, Barks JL, Kishore N, Morris DL (2010) Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond) 7:41","journal-title":"J Inflamm (Lond)"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05686-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05686-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05686-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T22:01:20Z","timestamp":1632520880000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05686-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,14]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["5686"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05686-8","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2021,5,14]]},"assertion":[{"value":"14 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not require ethical approval or informed consent because all the analyses were based on previously published data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}